Cover Image

PARP inhibition in prostate cancer

Defects in DNA damage repair genes are more common in prostate cancer than previously thought. These alterations provide an opportunity for precision oncology approaches and a number of studies have now shown that PARP inhibitors can have significant antitumor activity in men with DNA damage repair-...

Full description

Saved in:
Bibliographic Details
Main Authors: Nientiedt, Cathleen (Author) , Duensing, Anette (Author) , Zschäbitz, Stefanie (Author) , Jäger, Dirk (Author) , Hohenfellner, Markus (Author) , Stenzinger, Albrecht (Author) , Duensing, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: Genes, chromosomes & cancer
Year: 2021, Volume: 60, Issue: 5, Pages: 344-351
ISSN:1098-2264
DOI:10.1002/gcc.22903
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/gcc.22903
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/gcc.22903
Get full text
Author Notes:Cathleen Nientiedt, Anette Duensing, Stefanie Zschäbitz, Dirk Jäger, Markus Hohenfellner, Albrecht Stenzinger, Stefan Duensing
Description
Summary:Defects in DNA damage repair genes are more common in prostate cancer than previously thought. These alterations provide an opportunity for precision oncology approaches and a number of studies have now shown that PARP inhibitors can have significant antitumor activity in men with DNA damage repair-deficient metastatic castration-resistant prostate cancer. This review summarizes the key clinical trials related to the use of PARP inhibitors in prostate cancer. Besides clinical outcomes, toxicity, and PARP inhibitor resistance, the role of different DNA repair genes in the response to PARP inhibition will be discussed.
Item Description:First published: 21 October 2020
Gesehen am 06.12.2021
Physical Description:Online Resource
ISSN:1098-2264
DOI:10.1002/gcc.22903

Similar Items